Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24806584 | 0.87 | HTR1A (0.48) | HTR1ADRD2HTR6HTR2ASLC6A4 | |
| SCHEMBL12142434 | 0.81 | P2RX4 (0.47) | HTR1ADRD2HTR6HTR2ASLC6A4 | |
| SCHEMBL30472938 | 0.79 | CASP3 (0.46) | MEN1MAPTKMT2ACES1POLB | |
| SCHEMBL2156119 | 0.79 | CASP3 (0.46) | MEN1MAPTKMT2ACES1POLB | |
| SCHEMBL14288790 | 0.77 | DRD2 (0.58) | HTR1ADRD2HTR6HTR2ASLC6A4 | |
| SCHEMBL14516316 | 0.74 | CES1 (0.57) | CES1ALDH1A1BCHETTRCASP3 | |
| SCHEMBL26224662 | 0.73 | HTR1A (0.54) | HTR1ADRD2HTR6HTR2ASLC6A4 | |
| SCHEMBL23254941 | 0.73 | HTR1A (0.50) | HTR1ADRD2HTR6HTR2ASLC6A4 | |
| SCHEMBL21439922 | 0.72 | HTR1A (0.50) | HTR1ADRD2HTR6HTR2ASLC6A4 | |
| SCHEMBL25877102 | 0.72 | HTR1A (0.66) | HTR1ADRD2HTR6HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230226208-A1 | METHODS FOR THE PREPARATION OF BIOCONJUGATES | SYNAFFIX B.V. (NL) | 2023-07-20 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230127659-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | SYNAFFIX B.V. (NL) | 2023-04-27 | — | — | US | disclosed |
| US-11338043-B2 | Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates | SYNAFFIX B.V. (NL) | 2022-05-24 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| US-20210393792-A1 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2 | SYNAFFIX B.V. (NL) | 2021-12-23 | — | — | US | disclosed |
| US-20210353766-A1 | SULFAMIDE LINKERS FOR USE IN BIOCONJUGATES | SYNAFFIX B.V. (NL) | 2021-11-18 | — | — | US | disclosed |
| US-20210030886-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SYNAFFIX B.V. (NL) | 2021-02-04 | — | — | US | disclosed |
| US-10874746-B2 | Sulfamide linkers for use in bioconjugates | SYNAFFIX B.V. (NL) | 2020-12-29 | — | — | US | disclosed |
| US-10792369-B2 | Sulfamide linker, conjugates thereof, and methods of preparation | SYNAFFIX B.V. (NL) | 2020-10-06 | — | — | US | disclosed |
| US-20190262466-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | SYNAFFIX B.V. (NL) | 2019-08-29 | — | — | US | disclosed |
| US-20190262467-A1 | BIOCONJUGATES CONTAINING SULFAMIDE LINKERS FOR USE IN TREATMENT | SYNAFFIX B.V. (NL) | 2019-08-29 | — | — | US | disclosed |
| US-20190262468-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING CD30 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | SYNAFFIX B.V. (NL) | 2019-08-29 | — | — | US | disclosed |
| US-20190038765-A1 | IMPROVED SULFAMIDE LINKERS FOR USE IN BIOCONJUGATES | SYNAFFIX B.V. (NL) | 2019-02-07 | — | — | US | disclosed |
| US-20170298145-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SYNAFFIX B.V. (NL) | 2017-10-19 | — | — | US | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| US-9636421-B2 | Sulfamide linker, conjugates thereof, and methods of preparation | SYNAFFIX B.V. (NL) | 2017-05-02 | — | — | US | disclosed |
| US-20170072068-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SYNAFFIX B.V. (NL) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262467-A1 | BIOCONJUGATES CONTAINING SULFAMIDE LINKERS FOR USE IN TREATMENT | SULT1A1, SULT1E1, STS | HTR1A 2778/4885DRD2 3375/4885HTR6 3884/4885 |
| US-20190262466-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | FUT6, FUT5, FUT4 | HTR1A 947/4885DRD2 1163/4885HTR6 1684/4885 |
| US-20190262468-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING CD30 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | FUT4, FUT5, FUT6 | HTR1A 2414/4885DRD2 1876/4885HTR6 3455/4885 |
| US-20170298145-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SULT1E1, SULT1A1, SULT2A1 | HTR1A 847/4885DRD2 969/4885HTR6 2612/4885 |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | DNPEP, PAM, ASNS | HTR1A 1221/4885DRD2 1494/4885HTR6 766/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | HTR1A 4810/4885DRD2 3136/4885HTR6 4584/4885 |
| US-20190038765-A1 | IMPROVED SULFAMIDE LINKERS FOR USE IN BIOCONJUGATES | SP1, SPG11, CD22 | HTR1A 4275/4885DRD2 564/4885HTR6 3171/4885 |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | HTR1A 4404/4885DRD2 3943/4885HTR6 3637/4885 |
| US-10792369-B2 | Sulfamide linker, conjugates thereof, and methods of preparation | SULT1E1, SULT1A1, SULT2A1 | HTR1A 847/4885DRD2 969/4885HTR6 2612/4885 |
| US-10874746-B2 | Sulfamide linkers for use in bioconjugates | CD22, SPG11, SP1 | HTR1A 3942/4885DRD2 482/4885HTR6 3081/4885 |
| US-20170072068-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SULT1E1, SULT1A1, SULT2A1 | HTR1A 847/4885DRD2 969/4885HTR6 2612/4885 |
| US-20210353766-A1 | SULFAMIDE LINKERS FOR USE IN BIOCONJUGATES | CD22, SPG11, SP1 | HTR1A 4096/4885DRD2 442/4885HTR6 3384/4885 |
| US-20230226208-A1 | METHODS FOR THE PREPARATION OF BIOCONJUGATES | ZYX, ALG1, MLX | HTR1A 3800/4885DRD2 187/4885HTR6 4299/4885 |
| US-20210030886-A1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SULT1E1, SULT1A1, SULT2A1 | HTR1A 847/4885DRD2 969/4885HTR6 2612/4885 |
| US-11338043-B2 | Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates | FUT6, FUT5, FUT4 | HTR1A 947/4885DRD2 1163/4885HTR6 1684/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | HTR1A 4810/4885DRD2 3136/4885HTR6 4584/4885 |
| US-20210393792-A1 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2 | TESK2, ERBB2, TPD52L2 | HTR1A 4310/4885DRD2 402/4885HTR6 4118/4885 |
| US-20230127659-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | FUT6, FUT5, FUT4 | HTR1A 900/4885DRD2 1086/4885HTR6 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.